ACC, SVS join forces on single vascular registry

Jun 30, 2020


Effective January 2021, the ACC’S NCDR will collaborate with the SVS Vascular Quality Initiative (VQI) to support and steer a single vascular registry. SVS will operate the registry, creating a cobranded VQI program that will be a unique, comprehensive resource for measuring and improving the care provided to a growing population of patients with vascular diseases.

“The ACC NCDR and the SVS VQI are the two leading clinical registries in the peripheral vascular space. A single registry combines the resources and expertise from both organizations. We are merging the best elements of both registries to create the premier vascular clinical registry,” said VQI medical director Jens Eldrup-Jorgensen, MD. “We look forward to working with the ACC and other medical society collaborators that will allow us to enrich the VQI and improve the care of vascular patients.”

Originating as the CARE Registry in 2006 and expanding scope in 2014 to include lower extremity, vascular catheter-based interventions, the ACC’s Peripheral Vascular Intervention (PVI) Registry assesses the prevalence, demographics, management and outcomes of patients undergoing percutaneous treatment for peripheral vascular disease. To date, the PVI Registry includes patient data from more than 200 institutions.

VQI began in 2010 as an expansion of the Vascular Study Group of New England, which originated in 2003. More than 675 centers participate in VQI, which has 13 procedural-based registries encompassing the treatment of arterial and venous disease as well as a disease-based registry collecting data on the medical management of aneurysms, carotid stenosis and lower extremity arterial occlusive disease.

“The ACC is committed to working with all of our partners in cardiovascular care to create a cohesive source of vascular disease data,” said ACC president Athena Poppas, MD. “In combining our registry with that of SVS, we are providing uniform, actionable information for physicians and health systems.”

The new registry collaboration will provide greater opportunities to evaluate new and emerging technologies, pharmacologic therapies, and medical and lifestyle management. It will also provide a rich source of data for academicians, the FDA and industry looking to answer scientific questions about patient characteristics and outcomes and the use and effectiveness of different treatments.

“The SVS is proud of its history of working with other medical societies, government agencies and industry when developing quality improvement programs to improve the quality of vascular care,” said SVS president Ronald Dalman, MD. “Working with the ACC on this initiative is another example of how collaboration and inclusion can improve the services we offer to caregivers and our patients.”

Related Articles